Catalent, Inc. (NYSE:CTLT) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Catalent, Inc. (NYSE:CTLTGet Free Report) have been assigned a consensus rating of “Hold” from the twelve ratings firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $53.14.

A number of brokerages have recently issued reports on CTLT. StockNews.com initiated coverage on Catalent in a report on Thursday. They set a “sell” rating on the stock. Royal Bank of Canada restated a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a research report on Tuesday, February 20th. Finally, Stephens reaffirmed an “equal weight” rating and issued a $63.50 target price on shares of Catalent in a research report on Thursday, April 4th.

Read Our Latest Stock Analysis on Catalent

Catalent Price Performance

Shares of CTLT stock opened at $56.39 on Monday. The firm has a market cap of $10.21 billion, a P/E ratio of -9.24, a P/E/G ratio of 5.89 and a beta of 1.20. The business’s 50 day moving average price is $55.74 and its 200-day moving average price is $52.17. Catalent has a fifty-two week low of $31.80 and a fifty-two week high of $60.20. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.77 and a current ratio of 2.51.

Catalent (NYSE:CTLTGet Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. The firm had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.11 billion. On average, equities research analysts anticipate that Catalent will post 0.28 earnings per share for the current year.

Insider Activity at Catalent

In other Catalent news, insider Ricky Hopson sold 1,401 shares of the company’s stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total transaction of $76,018.26. Following the transaction, the insider now directly owns 20,617 shares in the company, valued at $1,118,678.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.31% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in Catalent by 1.8% in the third quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company’s stock worth $931,909,000 after acquiring an additional 365,648 shares in the last quarter. Tran Capital Management L.P. lifted its stake in Catalent by 12.2% in the 4th quarter. Tran Capital Management L.P. now owns 361,846 shares of the company’s stock valued at $16,258,000 after buying an additional 39,208 shares in the last quarter. Hsbc Holdings PLC increased its position in Catalent by 43.1% during the 3rd quarter. Hsbc Holdings PLC now owns 193,322 shares of the company’s stock worth $8,803,000 after purchasing an additional 58,240 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Catalent by 29.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,639,197 shares of the company’s stock worth $73,655,000 after acquiring an additional 376,931 shares during the period. Finally, SG Americas Securities LLC lifted its position in Catalent by 240.0% during the fourth quarter. SG Americas Securities LLC now owns 40,249 shares of the company’s stock worth $1,808,000 after buying an additional 28,410 shares during the period.

Catalent Company Profile

(Get Free Report

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.

Featured Stories

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.